At a glance
- Originator Toyama Chemical
- Class Antiplatelets; Antivirals; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Peripheral vascular disorders; Reperfusion injury; Transient ischaemic attacks; Unstable angina pectoris
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 31 Oct 2000 Phase-I clinical trials for Peripheral vascular disorders in United Kingdom (PO)
- 31 Oct 2000 Phase-I clinical trials for Reperfusion injury in United Kingdom (PO)